Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | CNR1 | P21554 | 6/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29549705 | 1.00 | CNR2 (1.00) | CNR2CNR1TDP1 | |
| SCHEMBL30472028 | 1.00 | CNR2 (1.00) | CNR2CNR1TDP1 | |
| SCHEMBL14746942 | 0.92 | CNR2 (0.88) | CNR2CNR1TDP1 | |
| SCHEMBL14746864 | 0.91 | CNR2 (0.86) | CNR2CNR1TDP1 | |
| SCHEMBL3422184 | 0.90 | CNR2 (0.88) | CNR2CNR1TDP1 | |
| SCHEMBL14746878 | 0.87 | CNR2 (0.82) | CNR2CNR1TDP1 | |
| SCHEMBL14746885 | 0.87 | CNR2 (0.79) | CNR2CNR1TDP1 | |
| SCHEMBL14746932 | 0.86 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL14746929 | 0.86 | CNR2 (0.81) | CNR2CNR1TDP1 | |
| SCHEMBL3021073 | 0.86 | CNR2 (1.00) | CNR2CNR1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2739262-B1 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | OREAL (FR) | 2017-09-27 | — | — | EP | claimed |
| EP-2739262-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2014-06-11 | — | — | EP | claimed |
| WO-2013021129-A2 | USE OF A CB1 RECEPTOR ANTAGONIST AS A WHITENING AND/OR ANTI-BROWNING AGENT FOR KERATIN MATERIAL | L'OREAL (FR) | 2013-02-14 | — | — | WO | claimed |
| US-8058264-B2 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2011-11-15 | — | — | US | claimed |
| WO-2008024408-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS FOR APPLICATION TO THE SKIN AND METHOD OF USE | THERAQUEST BIOSCIENCES, INC. (US) | 2008-02-28 | — | — | WO | claimed |
| WO-2008021394-A2 | PHARMACEUTICAL FORMULATIONS OF CANNABINOIDS AND METHOD OF USE | THERAQUEST BIOSCIENCES, LLC (US) | 2008-02-21 | — | — | WO | claimed |
| EP-1807063-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-07-18 | — | — | EP | claimed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | claimed |
| WO-2006045799-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-05-04 | — | — | WO | claimed |
| EP-3746064-B1 | COMPOUNDS FOR USE IN THE TREATMENT OF ACUTE BRAIN INJURY | UNIV COPENHAGEN (DK) | 2025-04-16 | — | — | EP | disclosed |
| US-20240391865-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | OTAGO INNOVATION LIMITED (NZ) | 2024-11-28 | — | — | US | disclosed |
| US-12077495-B2 | Compounds for the treatment of acute brain injury | Københavns Universitet (DK) | 2024-09-03 | — | — | US | disclosed |
| US-20230172874-A1 | USE OF CANNABIDIOL FOR THE TREATMENT OF INSOMNIA ASSOCIATED TO PAIN | GOBBI GABRIELLA (CA) | 2023-06-08 | — | — | US | disclosed |
| US-20210122700-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | UNIVERSITY OF OTAGO (NZ) | 2021-04-29 | — | — | US | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | SOLVAY PHARMACEUTICALS GMBH (DE) | 2007-11-01 | — | — | US | disclosed |
| EP-1807063-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | Solvay Pharmaceuticals GmbH (DE) | 2007-07-18 | — | — | EP | disclosed |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | ABBOTT PRODUCTS GMBH (DE) | 2006-06-15 | — | — | US | disclosed |
| WO-2006045799-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING CB1 CANNABINOID RECEPTOR ANTAGONISTS AND POTASSIUM CHANNEL OPENERS FOR THE TREATMENT OF DIABETES MELLITUS TYPE I, OBESITY AND RELATED CONDITIONS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-05-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12077495-B2 | Compounds for the treatment of acute brain injury | F2R, F2RL3, ARG2 | CNR2 336/4885CNR1 232/4885TDP1 3895/4885 |
| US-20210122700-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | F2R, F2RL3, ARG2 | CNR2 349/4885CNR1 260/4885TDP1 3992/4885 |
| US-20070254863-A1 | Use of CBx cannabinoid receptor modulators as potassium channel modulators | CNR2, CNR1, KCNN1 | CNR2 1/4885CNR1 2/4885TDP1 3902/4885 |
| US-20060128673-A1 | Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of obesity and related conditions | CNR1, CNR2, KCNJ11 | CNR2 2/4885CNR1 1/4885TDP1 4645/4885 |
| US-20240391865-A1 | COMPOUNDS FOR THE TREATMENT OF ACUTE BRAIN INJURY | F2R, F2RL3, ARG2 | CNR2 349/4885CNR1 260/4885TDP1 3992/4885 |
| US-20070254862-A1 | Pharmaceutical compositions comprising CBx cannabinoid receptor modulators and potassium channel modulators | CNR1, CNR2, KCNJ11 | CNR2 2/4885CNR1 1/4885TDP1 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.